BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30384014)

  • 1. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
    Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
    Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
    Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
    BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Kandel M; Dalle S; Bardet A; Allayous C; Mortier L; Dutriaux C; Guillot B; Leccia MT; Dalac S; Legoupil D; Saiag P; Montaudie H; Arnault JP; Brunet-Possenti F; Grob JJ; DeQuatrebarbes J; Beylot-Barry M; Lesimple T; Aubin F; Maubec E; Granel-Brocard F; Stoebner PE; Dupuy A; Dreno B; Michiels S; Lebbe C; Borget I
    Cancer; 2020 Feb; 126(3):611-618. PubMed ID: 31639198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
    Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
    Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
    Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
    Franken MG; Leeneman B; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; van der Veldt AAM; Westgeest HM; Wouters MWJM; Haanen JBAG; Uyl-de Groot CA
    ESMO Open; 2021 Dec; 6(6):100320. PubMed ID: 34856511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
    Henaine AM; Paubel N; Ducray F; Diebold G; Frappaz D; Guyotat J; Cartalat-Carel S; Aulagner G; Hartmann D; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2016 Feb; 41(1):47-53. PubMed ID: 26748577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
    Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with adverse events for systemic therapies in metastatic melanoma.
    Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
    J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
    Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
    Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.